001     163033
005     20240229133508.0
024 7 _ |a pmid:32893372
|2 pmid
024 7 _ |a 0270-9139
|2 ISSN
024 7 _ |a 1527-3350
|2 ISSN
024 7 _ |a doi: 10.1002/hep.31537.
|2 doi
037 _ _ |a DKFZ-2020-01824
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Barahona Ponce, Carol
|b 0
245 _ _ |a Gallstones, Body Mass Index, C-reactive Protein and Gallbladder Cancer - Mendelian Randomization Analysis of Chilean and European Genotype Data.
260 _ _ |a New York [u.a.]
|c 2021
|b Wiley Interscience
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1620734294_5121
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2021 May;73(5):1783-1796
520 _ _ |a Gallbladder cancer (GBC) is a neglected disease with substantial geographical variability: Chile shows the highest incidence worldwide, while GBC is relatively rare in Europe. Here we investigate the causal effects of risk factors considered in current GBC prevention programmes as well as C-reactive protein (CRP) level as a marker of chronic inflammation.We applied two-sample Mendelian randomization (MR) using publicly available data and our own data from a retrospective Chilean and a prospective European study. Causality was assessed by inverse variance weighted (IVW), MR-Egger regression and weighted median estimates complemented with sensitivity analyses on potential heterogeneity and pleiotropy, two-step MR and mediation analysis. We found evidence for a causal effect of gallstone disease on GBC risk in Chileans (p = 9 × 10-5 ) and Europeans (p = 9 × 10-5 ). A genetically elevated body mass index (BMI) increased GBC risk in Chileans (p = 0.03), while higher CRP concentrations increased GBC risk in Europeans (p = 4.1 × 10-6 ). European results suggest causal effects of BMI on gallstone disease (p = 0.008); public Chilean data were not, however, available to enable assessment of the mediation effects among causal GBC risk factors.Two risk factors considered in the current Chilean programme for GBC prevention are causally linked to GBC risk: gallstones and BMI. For Europeans, BMI showed a causal effect on gallstone risk, which was itself causally linked to GBC risk.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|x 0
|f POF IV
588 _ _ |a Dataset connected to PubMed,
700 1 _ |a Scherer, Dominique
|b 1
700 1 _ |a Brinster, Regina
|b 2
700 1 _ |a Boekstegers, Felix
|0 0000-0002-0587-7624
|b 3
700 1 _ |a Marcelain, Katherine
|b 4
700 1 _ |a Gárate, Valentina
|b 5
700 1 _ |a Müller, Bettina
|b 6
700 1 _ |a de Toro, Gonzalo
|b 7
700 1 _ |a Retamales, Javier
|b 8
700 1 _ |a Barajas, Olga
|b 9
700 1 _ |a Ahumada, Monica
|b 10
700 1 _ |a Morales, Erik
|b 11
700 1 _ |a Rojas, Armando
|b 12
700 1 _ |a Sanhueza, Verónica
|b 13
700 1 _ |a Loader, Denisse
|b 14
700 1 _ |a Rivera, María Teresa
|b 15
700 1 _ |a Gutiérrez, Lorena
|b 16
700 1 _ |a Bernal, Giuliano
|b 17
700 1 _ |a Ortega, Alejandro
|b 18
700 1 _ |a Montalvo, Domingo
|b 19
700 1 _ |a Portiño, Sergio
|b 20
700 1 _ |a Bertrán, Maria Enriqueta
|b 21
700 1 _ |a Gabler, Fernando
|b 22
700 1 _ |a Spencer, Loreto
|b 23
700 1 _ |a Olloquequi, Jordi
|b 24
700 1 _ |a Fischer, Christine
|b 25
700 1 _ |a Jenab, Mazda
|b 26
700 1 _ |a Aleksandrova, Krasimira
|b 27
700 1 _ |a Katzke, Verena
|0 P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4
|b 28
|u dkfz
700 1 _ |a Weiderpass, Elisabete
|0 0000-0003-2237-0128
|b 29
700 1 _ |a Bonet, Catalina
|b 30
700 1 _ |a Moradi, Tahereh
|b 31
700 1 _ |a Fischer, Krista
|b 32
700 1 _ |a Bossers, Willem
|b 33
700 1 _ |a Brenner, Hermann
|0 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2
|b 34
|u dkfz
700 1 _ |a Hveem, Kristian
|b 35
700 1 _ |a Eklund, Niina
|b 36
700 1 _ |a Völker, Uwe
|b 37
700 1 _ |a Waldenberger, Melanie
|b 38
700 1 _ |a Fuentes Guajardo, Macarena
|b 39
700 1 _ |a Gonzalez-Jose, Rolando
|b 40
700 1 _ |a Bedoya, Gabriel
|b 41
700 1 _ |a Bortolini, Maria C
|b 42
700 1 _ |a Canizales, Samuel
|b 43
700 1 _ |a Gallo, Carla
|b 44
700 1 _ |a Ruiz Linares, Andres
|b 45
700 1 _ |a Rothhammer, Francisco
|b 46
700 1 _ |a Lorenzo Bermejo, Justo
|b 47
773 _ _ |a 10.1002/hep.31537.
|0 PERI:(DE-600)1472120-x
|n 5
|p 1783-1796
|t Hepatology
|v 73
|y 2021
|x 0270-9139
909 C O |o oai:inrepo02.dkfz.de:163033
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 28
|6 P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 34
|6 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2
913 0 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-313
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Cancer risk factors and prevention
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2021
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2020-02-26
|w ger
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2020-02-26
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b HEPATOLOGY : 2018
|d 2020-02-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2020-02-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2020-02-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
|d 2020-02-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2020-02-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2020-02-26
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
|d 2020-02-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2020-02-26
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
|d 2020-02-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2020-02-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2020-02-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2020-02-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2020-02-26
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b HEPATOLOGY : 2018
|d 2020-02-26
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l C020 Epidemiologie von Krebs
|x 0
920 1 _ |0 I:(DE-He78)C070-20160331
|k C070
|l C070 Klinische Epidemiologie und Alternf.
|x 1
920 1 _ |0 I:(DE-He78)C120-20160331
|k C120
|l Präventive Onkologie
|x 2
920 1 _ |0 I:(DE-He78)HD01-20160331
|k HD01
|l DKTK HD zentral
|x 3
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a I:(DE-He78)C070-20160331
980 _ _ |a I:(DE-He78)C120-20160331
980 _ _ |a I:(DE-He78)HD01-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21